Genome Editing Comes of Age Achievements, Barriers and Futures
Jul 17-18, 2019
New York, United States of America
The specific goal for this meeting is to foster fruitful and creative interactions between researchers interested in applying these systems to genome engineering and related advances in a wide variety of organisms, together with scientists studying the basic biology of CRISPR-Cas and related bacterial defense systems.
This conference will bring together leaders and trainees from the cutting edge of CRISPR technologies and their application to genome editing and beyond. Academic, clinical, and industrial researchers are invited to share their recent discoveries to progress the field in CRISPR science and engineering.
Take away from this congress:
At the CRISPR-Cas Congress, not only discover how to adopt the latest techniques and methodologies, but learn how to improve the efficiency and delivery of CRISPR genome editing, minimizing unwanted off-target effects in the process. Maximize the potential for developing and commercializing superior agriculture products that boast desired traits but also accepted by the regulators and the end consumers.
Learn from case study presentations to ensure your CRISPR workflows are customized, minimize off-target effects and overcome key delivery challenges. Join the conversation with market leaders and innovators to cut through the avalanche of publications and extract maximum value from CRISPR genome engineering. Be part of the scientific meeting to make the most of greatest biotechnological breakthrough in a generation.
Exhibition and Sponsors:
Focused and high-level, the event will be an excellent platform to initiate new business relationships. With tailored networking, sponsors can achieve the face-to-face contact that overcrowded trade shows cannot deliver. Exhibiting and sponsorship options are extensive, and packages can be tailor-made to suit your individual company’s needs. Most packages include complimentary entry passes, targeted marketing to industry officials and executives, and bespoke networking opportunities.
“CRISPR” (pronounced “crispr”) stands for Clustered Regularly Interspaced Short Palindromic Repeats, which are the hallmark of a bacterial defense system that forms the basis for CRISPR-Cas9 genome editing technology. In the field of genome engineering, the term “CRISPR” or “CRISPR-Cas9” is often used loosely to refer to the various CRISPR-Cas9 and -CPF1, (and other) systems that can be programmed to target specific stretches of genetic code and to edit DNA at precise locations, as well as for other purposes, such as for new diagnostic tools. With these systems, researchers can permanently modify genes in living cells and organisms and, in the future, may make it possible to correct mutations at precise locations in the human genome in order to treat genetic causes of disease. Other systems are now available, such as CRISPR-Cas13’s, that target RNA provide alternate avenues for use, and with unique characteristics that have been leveraged for sensitive diagnostic tools, such as SHERLOCK.
CRISPR genome editing allows scientists to quickly create cell and animal models, which researchers can use to accelerate research into diseases such as cancer and mental illness. In addition, CRISPR is now being developed as a rapid diagnostic.
Studies using in vitro (laboratory) and animal models of human disease have demonstrated that the technology can be effective in correcting genetic defects. Examples of such diseases include cystic fibrosis, cataracts, and Fanconi anemia, according to a 2016 review article published in the journal Nature Biotechnology. These studies pave the way for therapeutic applications in humans.
CRISPR technology has also been applied in the food and agricultural industries to engineer probiotic cultures and to vaccinate industrial cultures (for yogurt, for example) against viruses. It is also being used in crops to improve yield, drought tolerance and nutritional properties.
One other potential application is to create gene drives. These are genetic systems, which increase the chances of a particular trait passing on from parent to offspring.
However, CRISPR-Cas9 is not without its drawbacks.
The genome-editing efficiencies can vary. According to the 2014 Science article by Doudna and Charpentier, in a study conducted in rice, gene editing occurred in nearly 50 percent of the cells that received the Cas9-RNA complex. Whereas other analyses have shown that depending on the target, editing efficiencies can reach as high as 80 percent or more.
There is also the phenomenon of "off-target effects," where DNA is cut at sites other than the intended target. This can lead to the introduction of unintended mutations.
DETAILS OF CRISPR IN 2019 IN New York, USA:
|CRISPR 2019||New York, USA||July 17-18, 2019|
Call for Submissions
- Structural Biology and Bioinformatics
- Genome editing and gene regulation in human health
- Plant and Animal Biotechnology
- Horizons of CRISPR biology
- Genome editing and gene regulation in industrial bacterial biotechnology
- CRISPR technologies beyond genome editing and gene regulation
- CRISPRCAS Revolution in Genome Editing
- CRISPR technologies and society
- Genome Editing Methods and Novel Tools
- Bioethics and Regulatory Compliance
- Origin and evolution of CRISPR-Cas systems
- Metabolic Engineering
- Exploring Cas9 diversity
- Genome Editing-The Future of Drug
- Therapeutic Genome Editing
- Cancer and Stem Cells